Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 2/20 | 0.41 |
| ▸ | BRD1 | O95696 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21218400 | 0.87 | CRBN (0.53) | CRBNRXFP1ACLYGLO1SLC40A1 | |
| SCHEMBL21218374 | 0.81 | CRBN (0.80) | CRBNRXFP1ACLYGLO1SLC40A1 | |
| SCHEMBL13049652 | 0.81 | CRBN (0.38) | CRBNSLC40A1MAPTCA12CA1 | |
| SCHEMBL1389185 | 0.79 | CA1 (0.52) | CRBNCA12CA1CA2CA3 | |
| SCHEMBL26844497 | 0.79 | CRBN (0.74) | CRBNRXFP1ACLYGLO1SLC40A1 | |
| SCHEMBL26844443 | 0.79 | CRBN (0.61) | CRBNRXFP1ACLYGLO1SLC40A1 | |
| SCHEMBL2768168 | 0.79 | SMN1; SMN2 (0.42) | CRBNRXFP1MAPTPGRCA12 | |
| SCHEMBL26844440 | 0.77 | CRBN (0.59) | CRBNRXFP1ACLYGLO1SLC40A1 | |
| SCHEMBL3060786 | 0.77 | CRBN (0.71) | CRBNRXFP1ACLYGLO1SLC40A1 | |
| SCHEMBL21218180 | 0.75 | CRBN (0.78) | CRBNRXFP1ACLYGLO1SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | claimed |
| EP-1258252-B1 | INTEGRIN EXPRESSION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | claimed |
| US-6469043-B1 | ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY | EISAI CO., LTD. (JP) | 2002-10-22 | — | — | US | claimed |
| EP-1074542-A1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | claimed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| JP-2010180229-A | SULFONAMIDE-CONTAINING INDOLE COMPOUND | EISAI R & D MANAGEMENT CO LTD | 2010-08-19 | — | — | JP | disclosed |
| EP-1258252-B1 | INTEGRIN EXPRESSION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090269352-A1 | ANTITUMOR AGENT COMPRISING SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND COMBINED WITH AN ANGIOGENESIS INHIBITOR | WAKABAYASHI TOSHIAKI | 2009-10-29 | — | — | US | disclosed |
| EP-1742052-A1 | Method for testing effect of angiogenesis inhibitor via integrin expression inhibition | Eisai Co., Ltd (JP) | 2007-01-10 | — | — | EP | disclosed |
| EP-1362601-B1 | METHOD OF EXAMINING EFFECT OF ANGIONEGESIS INHIBITOR MEDIATED BY THE INHIBITION OF INTEGRIN EXPRESSION | EISAI CO LTD (JP) | 2007-01-03 | — | — | EP | disclosed |
| JP-2006312652-A | SULFONAMIDE-CONTAINING INDOLE COMPOUND | EISAI R & D MANAGEMENT CO LTD | 2006-11-16 | — | — | JP | disclosed |
| US-6673787-B2 | PYRIMIDINESULFONAMIDE CONTAINING INDOLE COMPOUNDS USED AS ANTIANGIOGENIC AND ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1362601-A1 | METHOD OF EXAMINING EFFECT OF ANGIONEGESIS INHIBITOR MEDIATED BY THE INHIBITION OF INTEGRIN EXPRESSION | Eisai Co. Ltd (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6638964-B2 | Pyridinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents | EISAI CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-6469043-B1 | ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY | EISAI CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| EP-1074542-A1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269352-A1 | ANTITUMOR AGENT COMPRISING SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND COMBINED WITH AN ANGIOGENESIS INHIBITOR | FGF1, FGF2, FGFR1 | CRBN 2082/4885RXFP1 2153/4885ACLY 2148/4885 |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | CRBN 428/4885RXFP1 158/4885ACLY 1933/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | CRBN 319/4885RXFP1 1804/4885ACLY 4504/4885 |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | CRBN 482/4885RXFP1 149/4885ACLY 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.